ClinicalTrials.Veeva

Menu

Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study (PASS-PD)

U

University Hospital Schleswig-Holstein (UKSH)

Status

Enrolling

Conditions

Parkinson Disease

Treatments

Other: No intervention

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT04724941
PASS_PD_D440/2

Details and patient eligibility

About

The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.

Full description

The PASS-PP Study is designed to combine the latest developments in clinical and biomarker research to

  1. understand the distribution of risk profiles for PD in the general population, especially regarding non-motor symptoms
  2. identify subjects with a likelihood of developing PD
  3. follow individuals with a high likelihood/risk to develop PD in the future (compared to individuals with low risk and) in a prospective study
  4. understand the potential of biological markers to increase prediction of progression/conversion
  5. identify subtypes of PD patients, by providing a detailed clinical phenotyping with a main focus on non-motor symptoms cluster
  6. provide a framework of ethical handling of early risk disclosure in PD

Enrollment

2,000 estimated patients

Sex

All

Ages

50 to 99 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age between 50 and 99

Exclusion criteria

  • Presence of clinical PD at the time of study inclusion
  • Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis)
  • other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment
  • in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants)

Trial design

2,000 participants in 2 patient groups

REM behavior disorder +
Description:
Individuals with REM Sleep Behavior Disorder: All individuals will be included in a prospective, longitudinal observational study, including an annual investigation at the Department for Neurology (detailed anamnesis, neurological examination, motor assessment). Blood sampling will be performed every six months, non-motor symptoms will be assessed every three months using online surveys. All individuals can participate in an optional substudy including lumbar punctures every two years.
Treatment:
Other: No intervention
REM behavior disorder -
Description:
Individuals without REM Sleep Behavior Disorder with increased risk for PD: All individuals will be included in a prospective, longitudinal observational study, including an annual investigation at the Department for Neurology (detailed anamnesis, neurological examination, motor assessment). Blood sampling will be performed every six months, non-motor symptoms will be assessed every three months using online surveys. All individuals can participate in an optional substudy including lumbar punctures every two years.
Treatment:
Other: No intervention

Trial contacts and locations

1

Loading...

Central trial contact

Eva Schaeffer, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems